Ładuje się......
Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
BACKGROUND: The combination of bevacizumab and chemotherapy is still one of the standard treatments for advanced non-small-cell lung cancer (NSCLC) patients in the new era of targeted therapy. Although a high level of baseline lactate dehydrogenase (LDH) was found to predict survival benefit from be...
Zapisane w:
| Wydane w: | Onco Targets Ther |
|---|---|
| Główni autorzy: | , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove Medical Press
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166744/ https://ncbi.nlm.nih.gov/pubmed/30310292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S171566 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|